Background
Methods
Data sources
Study population
Exposure
Potential confounders
Statistical analysis
All patients (n = 3622) | Entire cohort | Propensity score-matched sample | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
PCI+ (n = 564) | PCI−/IHD+ (n = 3058) | SD* | PCI+ (n = 489) | PCI−/IHD+ (n = 489) | SD* | |||||||
Age, mean ± standard deviance | 74 | ± 7.8 | 72 | ± 7.1 | 74 | ± 7.9 | 0.209 | 73 | ± 7.1 | 73 | ± 7.7 | 0.015 |
Sex | 0.231 | 0.035 | ||||||||||
Female | 785 | (22) | 80 | (14) | 705 | (23) | 74 | (15) | 68 | (14) | ||
Male | 2837 | (78) | 484 | (86) | 2353 | (77) | 415 | (85) | 421 | (86) | ||
Cancer type | ||||||||||||
Colorectal cancer | 1165 | (32) | 195 | (35) | 970 | (32) | 0.061 | 174 | (36) | 170 | (35) | 0.005 |
Lung cancer | 910 | (25) | 115 | (20) | 795 | (26) | 0.133 | 103 | (21) | 104 | (21) | 0.005 |
Prostate cancer | 505 | (14) | 124 | (22) | 381 | (12) | 0.254 | 97 | (20) | 98 | (20) | 0.010 |
Gastric cancer | 1042 | (29) | 130 | (23) | 912 | (30) | 0.154 | 115 | (23) | 117 | (24) | 0.080 |
Cancer stage | ||||||||||||
In situ | 252 | (7) | 48 | (9) | 204 | (7) | 0.070 | 45 | (9) | 41 | (8) | 0.016 |
Localised | 1836 | (51) | 297 | (53) | 1539 | (50) | 0.047 | 253 | (52) | 249 | (51) | 0.030 |
Regional to lymph nodes involved | 471 | (13) | 68 | (12) | 403 | (13) | 0.034 | 61 | (12) | 66 | (14) | 0.052 |
Regional by direct extension | 399 | (11) | 78 | (14) | 321 | (11) | 0.102 | 66 | (14) | 75 | (15) | 0.050 |
Distant site(s)/node(s) involved | 579 | (16) | 53 | (9) | 526 | (17) | 0.231 | 48 | (10) | 41 | (8) | 0.011 |
Unknown | 85 | (2) | 20 | (3) | 65 | (2) | 0.086 | 16 | (3) | 17 | (4) | 0.056 |
Barthel index score | ||||||||||||
60–100 | 3206 | (89) | 489 | (87) | 2717 | (89) | 0.066 | 428 | (87) | 427 | (87) | 0.006 |
40–59 | 153 | (4) | 21 | (3) | 132 | (4) | 0.030 | 19 | (4) | 15 | (3) | 0.045 |
0–39 | 263 | (7) | 54 | (10) | 209 | (7) | 0.100 | 42 | (9) | 47 | (10) | 0.035 |
Overweight | 968 | (27) | 164 | (29) | 804 | (27) | 0.069 | 144 | (29) | 148 | (30) | 0.018 |
Current or past smoking | 1986 | (55) | 328 | (58) | 1685 | (54) | 0.090 | 283 | (58) | 277 | (57) | 0.025 |
Dyslipidemia | 1052 | (29) | 323 | (57) | 729 | (24) | 0.740 | 259 | (53) | 252 | (52) | 0.029 |
Hypertension | 1851 | (51) | 384 | (69) | 1467 | (48) | 0.417 | 320 | (65) | 319 | (65) | 0.004 |
Diabetes mellitus | 1179 | (33) | 261 | (46) | 918 | (30) | 0.319 | 217 | (44) | 219 | (45) | 0.008 |
Chronic kidney disease | 252 | (7) | 47 | (9) | 205 | (7) | 0.068 | 44 | (9) | 49 | (10) | 0.035 |
Congestive heart failure | 635 | (18) | 168 | (30) | 467 | (15) | 0.343 | 133 | (27) | 148 | (30) | 0.068 |
Atrial fibrillation | 309 | (9) | 63 | (11) | 246 | (8) | 0.091 | 52 | (11) | 47 | (10) | 0.034 |
β-blocker | 2773 | (77) | 230 | (41) | 619 | (20) | 0.476 | 185 | (38) | 187 | (38) | 0.008 |
Statin | 2499 | (69) | 306 | (54) | 817 | (27) | 0.610 | 255 | (52) | 259 | (53) | 0.016 |
ACE inhibitor | 296 | (8) | 90 | (16) | 206 | (7) | 0.303 | 68 | (14) | 71 | (14) | 0.012 |
ARB | 1472 | (41) | 204 | (36) | 959 | (31) | 0.118 | 182 | (37) | 191 | (39) | 0.038 |
Oral anti-coagulants | 447 | (12) | 68 | (12) | 379 | (12) | 0.002 | 63 | (13) | 64 | (13) | 0.006 |
Acute coronary syndrome | 650 | (18) | 185 | (33) | 465 | (15) | 0.416 | 134 | (27) | 129 | (26) | 0.023 |
Days from cancer diagnosis to PCI/IHD admission, median (IQR) | 78 | (31–384) | 274 | (98–607) | 65 | (27–325) | 0.555 | 250 | (85–588) | 279 | (48–599) | 0.015 |
Chemo/radiation/hormonal therapy | 1242 | (34) | 168 | (30) | 1074 | (35) | 0.119 | 143 | (29) | 156 | (32) | 0.058 |
Surgery or endoscopic resection | 2300 | (64) | 369 | (65) | 1931 | (63) | 0.058 | 323 | (66) | 322 | (66) | 0.004 |
Results
Long-term prognosis of cancer patients according to PCI
Long-term prognosis of patients with IHD undergoing PCI and those without IHD
All patients (n = 27,676) | Entire cohort | Propensity score-matched sample | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
PCI+ (n = 282) | PCI−/IHD+ (n = 27,392) | SD* | PCI+ (n = 280) | PCI−/IHD+ (n = 280) | SD* | |||||||
Age, mean ± standard deviance | 70 | ± 10.2 | 73 | ± 6.9 | 70 | ± 10.2 | 0.822 | 73 | ± 7.0 | 73 | ± 8.4 | 0.027 |
Sex | 0.444 | 0.077 | ||||||||||
Female | 8563 | (31) | 37 | (13) | 8526 | (31) | 37 | (13) | 30 | (11) | ||
Male | 19,111 | (69) | 245 | (87) | 18,866 | (69) | 243 | (87) | 250 | (89) | ||
Cancer type | ||||||||||||
Colorectal cancer | 9807 | (35) | 95 | (34) | 9712 | (35) | 0.037 | 95 | (34) | 97 | (35) | 0.015 |
Lung cancer | 5997 | (22) | 68 | (24) | 5929 | (22) | 0.059 | 67 | (24) | 62 | (22) | 0.042 |
Prostate cancer | 4317 | (16) | 55 | (20) | 4262 | (16) | 0.104 | 55 | (20) | 57 | (20) | 0.018 |
Gastric cancer | 7553 | (27) | 64 | (22) | 7489 | (27) | 0.107 | 63 | (22) | 64 | (23) | 0.009 |
Cancer stage | ||||||||||||
In situ | 2569 | (9) | 21 | (7) | 2548 | (9) | 0.067 | 21 | (7) | 13 | (5) | 0.120 |
Localised | 12,738 | (46) | 148 | (52) | 12,590 | (46) | 0.131 | 147 | (53) | 163 | (58) | 0.115 |
Regional to lymph nodes involved | 2924 | (11) | 39 | (14) | 2885 | (11) | 0.101 | 39 | (14) | 31 | (11) | 0.086 |
Regional by direct extension | 2818 | (10) | 36 | (13) | 2782 | (10) | 0.082 | 35 | (12) | 38 | (14) | 0.032 |
Distant site(s)/node(s) involved | 5852 | (21) | 31 | (11) | 5821 | (21) | 0.282 | 31 | (11) | 32 | (11) | 0.011 |
Unknown | 773 | (3) | 7 | (3) | 766 | (3) | 0.020 | 7 | (3) | 3 | (1) | 0.108 |
Barthel index score | ||||||||||||
60–100 | 25,701 | (93) | 267 | (95) | 25,434 | (93) | 0.076 | 265 | (95) | 264 | (94) | 0.016 |
40–59 | 694 | (2) | 3 | (1) | 691 | (2) | 0.110 | 3 | (1) | 2 | (1) | 0.038 |
0–39 | 1279 | (5) | 12 | (4) | 1267 | (5) | 0.018 | 12 | (4) | 14 | (5) | 0.034 |
Overweight | 6116 | (22) | 85 | (30) | 6031 | (22) | 0.186 | 84 | (30) | 85 | (30) | 0.008 |
Current or past smoking | 14,138 | (51) | 168 | (60) | 13,970 | (51) | 0.173 | 166 | (59) | 165 | (59) | 0.007 |
Dyslipidemia | 562 | (2) | 16 | (6) | 546 | (2) | 0.193 | 15 | (5) | 13 | (5) | 0.033 |
Hypertension | 1393 | (5) | 29 | (10) | 1364 | (5) | 0.201 | 27 | (10) | 19 | (7) | 0.104 |
Diabetes mellitus | 1137 | (4) | 34 | (12) | 1103 | (4) | 0.299 | 32 | (11) | 23 | (8) | 0.108 |
Chronic kidney disease | 220 | (1) | 13 | (5) | 207 | (1) | 0.240 | 11 | (4) | 8 | (3) | 0.059 |
Congestive heart failure | 250 | (1) | 11 | (4) | 239 | (1) | 0.199 | 9 | (3) | 4 | (1) | 0.119 |
Atrial fibrillation | 308 | (1) | 0 | (0) | 308 | (1) | 0.151 | 0 | (0) | 0 | (0) | NA |
β-blocker | 562 | (2) | 31 | (11) | 532 | (2) | 0.374 | 28 | (10) | 23 | (8) | 0.062 |
Statin | 1251 | (5) | 46 | (16) | 1205 | (4) | 0.399 | 44 | (16) | 44 | (16) | 0.000 |
ACE inhibitor | 301 | (1) | 9 | (3) | 292 | (1) | 0.065 | 9 | (3) | 2 | (1) | 0.181 |
ARB | 1755 | (6) | 49 | (17) | 1707 | (6) | 0.343 | 46 | (16) | 43 | (15) | 0.029 |
Oral anti-coagulants | 247 | (1) | 8 | (3) | 239 | (1) | 0.060 | 8 | (3) | 3 | (1) | 0.129 |
Acute coronary syndrome | – | – | 81 | (29) | – | – | NA | 81 | (29) | – | – | NA |
Days from cancer diagnosis to PCI/IHD admission, median (IQR) | – | – | 243 | (92–543) | – | – | NA | 242 | (90–547) | – | – | NA |
Chemo/radiation/hormonal therapy | 10,220 | (37) | 97 | (34) | 10,123 | (37) | 0.079 | 97 | (35) | 94 | (34) | 0.023 |
Surgery or endoscopic resection | 16,624 | (60) | 189 | (67) | 16,435 | (60) | 0.216 | 188 | (67) | 194 | (69) | 0.046 |